Script data, script data, on the wall, who’s the worst bio-dreck of them all? – KERX, GALE, MNKD

One of our favorite things to do at BuyersStrike! HQ is make fun of investors, usually retail, the sell side shills that prey on them, or very inexperienced buy-siders, who use ridiculous jargon like “PPS”, “uplist” and a new favorite “de-risked.”

Many investors seem to believe that with an approved drug a company magically becomes “de-risked”. In actuality, getting a drug approved (or buying an already approved drug) is only the beginning of the struggle for bio-dreck companies, moron management teams, and bagholder investors.

Presented for our, and hopefully your, amusement, is a graph of some of the very worst drug launches in recent memory.

(more…)

Vascular Biogenics and Schroedinger’s Trial Subjects – VBLT

Hard to believe it was only two weeks ago when the intrepid team at Neuralstem (CUR) issued a press release that showed they have mastered the ability to move back and forth along a linear timestream (catch up on that here). This week the crew at scandal plagued Vascular Biogenics (VBLT) has actually made that achievement look positively mundane.

VBLT has proven what quantum theory had long suggested, that quantum super-positioning exists. And perhaps VB-111 is the substance that can enable travel even Leary never thought possible.

Intrigued? Read on.

(more…)

What makes Neuralstem so incredible? (CUR)

If you have been following @buyersstrike on Twitter, you might see the occasional tweet about Neuralstem (CUR). Over here at BuyersStrike! HQ we find Neuralstem to be absolutely incredible. It takes a lot to stand above the crowd in the current world of bio-dreck mania. So, what makes this 2006 direct to the OTC-BB company so fascinating?

Well, the thing that makes this company so incredibly amazing (if they can successfully patent and commercialize) could make the company worth more than Apple, Tesla, Google, combined! Yes, more than all of them. Intrigued? Read on….

(more…)

Galena Gets Smacked Down Again, Hard. – GALE

To add to its mounting legal woes, the pathetic tools inept fools at Galena Biopharma (GALE) were smacked down yet again by Judge Michael H. Simon in US District Court.

The fentanyl pushing, stock promoting, scum at Galena have been attempting to quash a lawsuit brought by shareholders who, quite rightly, are demanding answers and accountability from the company for the DreamTeam stock promotion scandal. Readers might remember our attempted site visit to DreamTeam HQ. This scandal has already cost Galena CEO Mark Ahn his job.

Thankfully, Judge Simon has seen through Galena’s latest attempt to stall discovery, and the lawsuit will move forward.

The following is the full text of the most recent decision:

(more…)

Protocol Deviations And The One Site to Rule Them All – AMPE

Our post last week on Freezergate 14, “Every Picture…” has caused quite a stir. Today Ampion (AMPE)  has issued a “Letter To Shareholders” available here attempting to gloss over some of the Freezergate ’14 issues.

Don’t worry shareholders, these things happen all the time and the FDA is “very positive” as this particularly choice bit suggests:

(more…)

Every Picture Tells A Story – AMPE, the (other) Dream Team & Raghuram Selvaraju

Today’s story begins with an aging office park, 500 arthritic Phase III subjects and a freezer that eats dreams. Welcome, dear readers, to the world of Ampio Pharmaceuticals (AMPE), the filthy reverse merger put together by Las-Vegas-based stock promoter Jens Dalsgaard, charming the market this week with tales from Freezergate ’14 (read more about Freezergate here).
Sell-side shill Raghuram Selvaraju, of Aegis Capital, brushed off Freezergate as an innocent distribution error in his report of 21 August 2014 (emphasis mine):

 This morning, Ampio Pharmaceuticals announced a delay in the data analysis of the STEP study due to the fact that the study drug (both AmpionTM and the placebo) were exposed to lower temperatures than permitted by the drug specifications during shipment to the clinical sites….During the review of all documentation following the unblinding of the study, the company’s independent Clinical Research Organization discovered that the drug product received at the clinical sites had been below the temperature requirement of 15 degrees Celsius and may have been frozen for some period of time.

Innocent enough? Hardly. All Ram is doing is regurgitating the company line, spinning what most certainly be failure into platitudes and excuses designed to keep suckers buying paper that likely is only worth the cash on the balance sheet, roughly $1.25 per share. But what really jumped out at us was a creative use of the plural (clinical sites?) and a funny definition of the word “independent”. We were recently in sunny SoCal and investigted this independent CRO, which just happened to share a wall with the study’s sole site and Principal Investigator (“PI”). Coincidence?

(more…)

Quick Take – Bye Bye Mark Ahn (GALE)

As tweeted last night by The Street.com’s Adam Feuerstein, the smug Mark Ahn is out at dreadful Galena Biopharmaceutical (GALE). Read more here.

The sell-side analysts whoring themselves out for banking business, like Needham’s moronic Chad Messer (read about him here and here) will now have to dust off the pads and kneel before newly promoted GALE CEO Mark Schwartz.

For those playing at home, the case to watch (or better yet send in an FOIA request) is:

In the Matter of Galena Biopharma, SEC File No. HO 12356 now known as  “In the Matter of Certain Stock Promotions”

No wonder the GALE-eediots have been so silent recently.

THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.